Coupled with the findings of the present study, these data suggest that myostatin likely contributes to alterations in skeletal muscle quantity, quality and metabolism in conditions of obesity and T2DM and a pharmacological strategy to disrupt myostatin signaling may potentially prevent, attenuate or reverse their progression. This evidence concerns the gene MSTN and type 2 diabetes mellitus.